PCN57 - Costs Associated with Health Care Resource Use in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Treatment with Pazopanib Versus Sunitinib
Autor: | Hackshaw, M.D., Hansen, R.N., Nagar, S.P., Arondekar, B., Deen, K.C., Sullivan, S.D., Ramsey, S.D. |
---|---|
Zdroj: | In Value in Health May 2014 17(3):A77-A78 |
Databáze: | ScienceDirect |
Externí odkaz: |